naa a22 4500 510764568 CHVBK 20180411083152.0 cr unu---uuuuu 180411e20131101xx s 000 0 eng 10.1007/s12094-013-1035-z doi (NATIONALLICENCE)springer-10.1007/s12094-013-1035-z Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers? [Elektronische Daten] [D. Marquez-Medina, A. Chachoua, A. Martin-Marco, A. Desai, V. Garcia-Reglero, A. Salud-Salvia, F. Muggia] Purpose: Advanced non-small cell lung cancer (NSCLC) is a common and lethal malignancy that has rarely benefited from chemotherapy. Erlotinib is highly effective in NSCLC patients selected by clinical characteristics and/or the presence of epidermal growth factor receptor-sensitizing mutations. However, the way to delay or bypass erlotinib resistance is not systematically addressed. Different erlotinib-failure modes have been reported in NSCLC, and strategies to prolong erlotinib efficacy are perhaps adaptable to them. We report the feasibility and efficacy of continued erlotinib maintenance and local salvage radiation to overcome erlotinib resistances in selected NSCLC patients. Patients and methods: Thirty of 52 consecutive erlotinib-treated advanced NSCLC from the NYU Langone Medical Center and the Arnau de Vilanova Hospital of Lleida responded initially to erlotinib. Twenty-six patients eventually showed a generalized-progression to erlotinib, and four progressed in solitary tumor sites. These four patients were treated with continued erlotinib maintenance and local salvage radiation. Results: The progression-free survival (PFS) was statistically similar in patients with oligo or generalized-progression to erlotinib. However, all four cases with solitary-progression did benefit from continued erlotinib maintenance and salvage radiation with 41-140% prolongation of PFS. It was reflected in an improved overall survival when they were compared with patients with generalized-progression (76.4 vs. 19.9months; p=0.018). Conclusion: Continued erlotinib maintenance and local salvage radiation is feasible and could contribute to a better outcome in selected NSCLC patients with solitary-progression to erlotinib. Prospective randomized trials of this strategy are warranted. Federación de Sociedades Españolas de Oncología (FESEO), 2013 Disease progression nationallicence Epidermal growth factor receptor nationallicence Erlotinib nationallicence Gefitinib nationallicence Non-small cell lung cancer nationallicence Salvage radiation nationallicence Marquez-Medina D. Medical Oncology Department, University Hospital Arnau de Vilanova, Avda. Rovira Roure, Lleida, Spain aut Chachoua A. Medical Oncology, NYU Cancer Institute and Langone Medical Center, New York, USA aut Martin-Marco A. Medical Oncology Department, University Hospital Arnau de Vilanova, Avda. Rovira Roure, Lleida, Spain aut Desai A. Medical Oncology, NYU Cancer Institute and Langone Medical Center, New York, USA aut Garcia-Reglero V. Radiation Oncology Department, U. H. Arnau de Vilanova, Lleida, Spain aut Salud-Salvia A. Medical Oncology Department, University Hospital Arnau de Vilanova, Avda. Rovira Roure, Lleida, Spain aut Muggia F. Medical Oncology, NYU Cancer Institute and Langone Medical Center, New York, USA aut Clinical and Translational Oncology Springer Milan 15/11(2013-11-01), 959-964 1699-048X 15:11<959 2013 15 12094 https://doi.org/10.1007/s12094-013-1035-z text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-013-1035-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Marquez-Medina D. Medical Oncology Department, University Hospital Arnau de Vilanova, Avda. Rovira Roure, Lleida, Spain aut NATIONALLICENCE 700 1- Chachoua A. Medical Oncology, NYU Cancer Institute and Langone Medical Center, New York, USA aut NATIONALLICENCE 700 1- Martin-Marco A. Medical Oncology Department, University Hospital Arnau de Vilanova, Avda. Rovira Roure, Lleida, Spain aut NATIONALLICENCE 700 1- Desai A. Medical Oncology, NYU Cancer Institute and Langone Medical Center, New York, USA aut NATIONALLICENCE 700 1- Garcia-Reglero V. Radiation Oncology Department, U. H. Arnau de Vilanova, Lleida, Spain aut NATIONALLICENCE 700 1- Salud-Salvia A. Medical Oncology Department, University Hospital Arnau de Vilanova, Avda. Rovira Roure, Lleida, Spain aut NATIONALLICENCE 700 1- Muggia F. Medical Oncology, NYU Cancer Institute and Langone Medical Center, New York, USA aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/11(2013-11-01), 959-964 1699-048X 15:11<959 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer